Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "inflammatory"

198 News Found

BioAge Labs doses first patient in BGE-102 phase 1 trial
Biotech | August 19, 2025

BioAge Labs doses first patient in BGE-102 phase 1 trial

The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants


Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India
Drug Approval | August 11, 2025

Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India

NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India


Primelaze introduces Q-Switched Nd:YAG laser technology in India for skin treatments
News | August 08, 2025

Primelaze introduces Q-Switched Nd:YAG laser technology in India for skin treatments

The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation


Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines
News | August 06, 2025

Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines

Vasograin Plus represents a major advancement in the treatment of migraine


Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US
News | July 17, 2025

Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva


Zydus receives final approval from USFDA for Celecoxib Capsules
Drug Approval | July 15, 2025

Zydus receives final approval from USFDA for Celecoxib Capsules

Celecoxib is a nonsteroidal anti-inflammatory drug


FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%
Drug Approval | July 15, 2025

FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%

Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,


Merck to acquire Verona Pharma for US$ 10 billion
News | July 10, 2025

Merck to acquire Verona Pharma for US$ 10 billion

Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases


Sanofi exercises license extension option to Nurix’s STAT6 program
Biopharma | June 04, 2025

Sanofi exercises license extension option to Nurix’s STAT6 program

his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days